Thornburg Investment Management Inc. Has $2.46 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Key Points

• Thornburg Investment Management increased its BioMarin holdings by 305.9% in the second quarter, bringing its position to 43,061 shares valued at approximately $2.46 million. Institutional investors and hedge funds collectively own 98.71% of BMRN shares.
• BioMarin reported quarterly EPS of $1.20, beating estimates of $0.95, while revenue rose 20% year over year to $989.71 million. The company issued fiscal 2026 EPS guidance of $4.90 to $5.10.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $88.79, despite mixed rating changes and a current share price of $64.67.

Thornburg Investment Management Inc. lifted its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 305.9% in the second quarter, according to its most recent filing with the SEC. The firm owned 43,061 shares of the biotechnology company's stock after acquiring an additional 32,453 shares during the period. Thornburg Investment Management Inc.'s holdings in BioMarin Pharmaceutical were worth $2,464,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in BMRN. Primecap Management Co. CA acquired a new position in BioMarin Pharmaceutical in the second quarter worth about $811,962,000. Norges Bank acquired a new stake in BioMarin Pharmaceutical during the fourth quarter valued at approximately $447,572,000. Vestal Point Capital LP boosted its holdings in BioMarin Pharmaceutical by 261.4% during the fourth quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company's stock valued at $178,290,000 after purchasing an additional 2,170,000 shares in the last quarter. Viking Global Investors LP grew its stake in shares of BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company's stock valued at $675,505,000 after purchasing an additional 1,488,552 shares during the period. Finally, Caisse de depot et placement du Quebec bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at approximately $70,749,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock opened at $64.67 on Friday. The stock has a 50-day simple moving average of $61.70 and a 200 day simple moving average of $58.15. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. BioMarin Pharmaceutical Inc. has a 12-month low of $49.26 and a 12-month high of $70.98. The stock has a market capitalization of $12.52 billion, a price-to-earnings ratio of 174.78, a P/E/G ratio of 0.46 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts' consensus estimates of $0.95 by $0.25. The firm had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company's revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, research analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on BMRN shares. Weiss Ratings downgraded BioMarin Pharmaceutical from a "hold (c-)" rating to a "sell (d)" rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Piper Sandler increased their price objective on BioMarin Pharmaceutical from $82.00 to $88.00 and gave the stock an "overweight" rating in a research note on Monday, August 17th. Bank of America cut their price objective on BioMarin Pharmaceutical from $85.00 to $80.00 and set a "buy" rating for the company in a report on Tuesday, May 19th. Finally, Barclays boosted their target price on shares of BioMarin Pharmaceutical from $105.00 to $111.00 and gave the company an "overweight" rating in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, BioMarin Pharmaceutical has a consensus rating of "Moderate Buy" and an average target price of $88.79.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source